BCM
SGNT

Brookstone Capital Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Brookstone Capital Management’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-247
Closed -$6K – 2239
2015
Q2 		$6K Buy
+247
New +$5.92K ﹤0.01% 1442

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Brookstone Capital Management's SGNT Position: Q3 2015 in Review

Brookstone Capital Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2015, closing a stake of 247 shares — an estimated $6K sold.

Brookstone Capital Management first reported a position in SGNT in Q2 2015 and held it in 1 quarter. The position peaked at $6K in Q2 2015. 127 funds tracked by Wall St. Rank hold SGNT as of Q3 2015.

  • Brookstone Capital Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2015 after selling out during the quarter.
  • Brookstone Capital Management sold 247 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2015, an estimated $6K.
  • Brookstone Capital Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2015 and held it in 1 quarter.
  • Brookstone Capital Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $6K in Q2 2015.
  • 127 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2015.

Based on Brookstone Capital Management's 13F filing for Q3 2015, filed 28 Oct 2015.